Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China
Table 1
Demographic and clinicopathologic characteristics in the present study.
Subject characteristics
Total cohort
Construction cohort
Validation cohort
χ2
value
N (%)
N (%)
N (%)
Age
18–45
134 (39.1)
98 (40.3)
36 (36.0)
0.594
0.743
46–55
109 (31.8)
75 (30.9)
34 (34.0)
>55
100 (29.2)
70 (28.8)
30 (30.0)
Marital status
Married
324 (94.5)
228 (93.8)
96 (96.0)
0.639
0.424
Unmarried
19 (5.5)
15 (6.2)
4 (4.0)
History of smoking
Yes
17 (5.0)
11 (4.5)
6 (6.0)
0.326
0.568
No
326 (95.0)
232 (95.5)
94 (94.0)
Alcohol consumption
Yes
14 (4.1)
12 (4.9)
2 (2.0)
1.562
0.211
No
329 (95.9)
231 (95.1)
98 (98.0)
Menstrual status
Menstruation
108 (31.5)
80 (32.9)
28 (28.0)
0.796
0.372
Menopause
235 (68.5)
163 (67.1)
72 (72.0)
History of abortion
No
236 (68.8)
162 (66.7)
74 (74.0)
1.775
0.183
Yes
107 (31.2)
81 (33.3)
26 (26.0)
Family history of tumor
Yes
83 (24.2)
61 (25.1)
22 (22.0)
0.372
0.542
No
260 (75.8)
182 (74.9)
78 (78.0)
ABO blood type
A type
90 (26.2)
66 (27.2)
24 (24.0)
0.549
0.908
B type
116 (33.8)
82 (33.7)
34 (34.0)
AB type
46 (13.4)
31 (12.8)
15 (15.0)
O type
91 (26.5)
64 (26.3)
27 (27.0)
HGB
115–150 g/L
276 (80.5)
194 (79.8)
82 (82.0)
0.227
0.893
<115 g/L
59 (17.2)
43 (17.7)
16 (16.0)
>150 g/L
8 (2.3)
6 (2.5)
2 (2.0)
CA153
0–25 U/ml
113 (32.9)
75 (30.9)
38 (38.0)
1.633
0.201
>25 U/ml
230 (67.1)
168 (69.1)
62 (62.0)
CEA
0–5 ng/ml
171 (49.9)
116 (47.7)
55 (55.0)
1.495
0.221
>5 ng/ml
172 (50.1)
127 (52.3)
45 (45.0)
ALP
50–135 U/L
227 (66.2)
164 (67.5)
63 (63.0)
0.659
0.719
<50 U/L
26 (7.6)
18 (7.4)
8 (8.0)
>135 U/L
90 (26.2)
61 (25.1)
29 (29.0)
Serum calcium
2.10–2.55 mmol/L
228 (66.5)
165 (67.9)
63 (63.0)
1.050
0.592
<2.10 mmol/L
38 (11.1)
27 (11.1)
11 (11.0)
>2.55 mmol/L
77 (22.4)
51 (21.0)
26 (26.0)
Pathology
Ductal carcinoma
219 (63.8)
155 (63.8)
64 (64.0)
0.001
0.970
Others
124 (36.2)
88 (36.2)
36 (36.0)
Grade
I-II
238 (69.4)
172 (70.8)
66 (66.0)
0.763
0.382
III
105 (30.6)
71 (29.2)
34 (34.0)
Tumor size
<2 cm
123 (35.9)
80 (32.9)
43 (43.0)
3.187
0.203
2–5 cm
175 (51.0)
129 (53.1)
46 (46.0)
>5 cm
45 (13.1)
34 (14)
11 (11.0)
Lymph node metastasis
Yes
276 (80.5)
198 (81.5)
78 (78.0)
0.546
0.460
No
67 (19.5)
45 (18.5)
22 (22.0)
ER status
Positive
237 (69.1)
165 (67.9)
72 (72.0)
0.557
0.455
Negative
106 (30.9)
78 (32.1)
28 (28.0)
PR status
Positive
194 (56.6)
134 (55.1)
60 (60.0)
0.680
0.410
Negative
149 (43.4)
109 (44.9)
40 (40.0)
Her-2 status
Positive
74 (21.6)
51 (21.0)
23 (23.0)
0.170
0.681
Negative
269 (78.4)
192 (79.0)
77 (77.0)
Ki-67 status
Positive
87 (25.4)
60 (24.7)
27 (27.0)
0.199
0.655
Negative
256 (74.6)
183 (75.3)
73 (73.0)
Surgery for BC
Yes
262 (76.4)
186 (76.5)
76 (76.0)
0.012
0.914
No
81 (23.6)
57 (23.5)
24 (24.0)
Chemotherapy
No
21 (6.1)
11 (4.5)
10 (10.0)
3.692
0.055
Yes
322 (93.9)
232 (95.5)
90 (90.0)
Radiotherapy
No
225 (65.6)
160 (65.8)
65 (65.0)
0.022
0.881
Yes
118 (34.4)
83 (34.2)
35 (35.0)
Endocrinotherapy
No
183 (53.4)
129 (53.1)
54 (54.0)
0.024
0.878
Yes
160 (46.6)
114 (46.9)
46 (46.0)
Targeted therapy
No
302 (88.0)
212 (87.2)
90 (90.0)
0.512
0.474
Yes
41 (12.0)
31 (12.8)
10 (10.0)
Time of BM
SBM
148 (43.1)
104 (42.8)
44 (44.0)
0.042
0.838
MBM
195 (56.9)
139 (57.2)
56 (56.0)
Radiotherapy for BM
No
283 (82.5)
202 (83.1)
81 (81.0)
0.222
0.637
Yes
60 (17.5)
41 (16.9)
19 (19.0)
Pathological fracture
No
310 (90.4)
222 (91.4)
88 (88.0)
0.919
0.338
Yes
33 (9.6)
21 (8.6)
12 (12.0)
Spinal cord compression
No
333 (97.1)
236 (97.1)
97 (97.0)
0.004
0.952
Yes
10 (2.9)
7 (2.9)
3 (3.0)
Surgery for BM
No
334 (97.4)
237 (97.5)
97 (97.0)
0.078
0.780
Yes
9 (2.6)
6 (2.5)
3 (3.0)
Performance of BPs
No
84 (24.5)
56 (23.0)
28 (28.0)
0.941
0.332
Yes
259 (75.5)
187 (77.0)
72 (72.0)
Liver metastasis
No
224 (65.3)
155 (63.8)
69 (69.0)
0.850
0.357
Yes
119 (34.7)
88 (36.2)
31 (31.0)
Brain metastasis
No
307 (89.5)
217 (89.3)
90 (90.0)
0.037
0.848
Yes
36 (10.5)
26 (10.7)
10 (10.0)
Lung metastasis
No
206 (60.1)
147 (60.5)
59 (59.0)
0.066
0.797
Yes
137 (39.9)
96 (39.5)
41 (41.0)
Other organs metastasis
No
267 (77.8)
191 (78.6)
76 (76.0)
0.278
0.598
Yes
76 (22.2)
52 (21.4)
24 (24.0)
HGB: hemoglobin; CA153: carbohydrate antigen 153; CEA: carcinoembryonic antigen; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.